Maybe this post header could be retained for information...

Maybe this post header could be retained for information relating to relevant info...... as far as our drug GDC 0084 and a number of imminent conferences and  presentations by Dr Brastianos.

Dr Brastianos will chair and present a Brain Metastases lecture in Vienna this week. I also have links where she will be attending two other world brain cancer conventions in coming weeks. Any future info presented here would be very interesting to say the least. (more to follow on the role of Dr Brastianos)

https://www.massgeneral.org/cancer/assets/pdfs/Einladung_BMA_28_29062019_v08web.pdf[/BCOLOR]


--------
As most here would know....Dr Brastianos from Harvard Uni/Dana Farber Hospital Institute has undertaken a lot of research into PI3K Inhibitors and their role in fighting cancer. In particular her interest is Breast Brain metastases.

Research presented here on the board, would suggest KZA drug GDC 0084 is at the for front of Dr Brastianos research. In Dana Farbers decision to approach Kazia last year to undertake an FDA Breast Brain cancer trial.......it would seem, her recommendation may have played a role. Dana Farber has only one current PI3K Breast Brain cancer trial currently taking place at their hospital....which is GDC 0084.

But of even more significance and to back up the views of these world experts on GDC 0084 ....is this from a few weeks ago:  

Kazia Enters Clinical Collaboration for Metastatic Brain Cancer with Alliance for Clinical Trials in Oncology
SYDNEY, May 20, 2019 /PRNewswire/ -- Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to announce that it has entered into a collaboration with the Alliance for Clinical Trials in Oncology Foundation (Alliance), a US-based cancer research network sponsored by the National Cancer Institute. Alliance will launch a multi-centre phase II study to investigate the potential use of Kazia's investigational new drug, GDC-0084, alongside several other targeted cancer therapies, in the treatment of brain metastases (cancer that has spread to the brain).
"Brain metastases truly represent an unmet clinical need," said Priscilla Brastianos, MD, Principal Investigator of the study, and Assistant Professor of Medicine at Harvard Medical School. "We urgently need to find better treatment options for these patients. We hope this study will help us identify a new treatment paradigm." Dr Brastianos is also an Assistant Physician in Medicine in the Department of Hematology/Oncology at Massachusetts General Hospital. Her research interests focus on metastatic brain cancer, and she has been extensively published in this field. Dr Brastianos will be joined on the study Steering Committee by distinguished expert clinicians from leading centres across the United States.​

_______________________________________________________

In posting here on this stock, at the moment....everybody will have their views on the SP.

The decision by Dr Brastianos only a few weeks ago, with access to how 2 other GDC trials are proceeding at her hospital Dana Farber…….is surely the most defining and relevant key information.....or do you consider a seller of so far a relative few shares, for whatever reason is unknow - MORE IMPORTANT THAN ALLIANCE decision a month ago to select our drug. (There are over 1000 FDA trials currently in progress at Dana Farber - the other two drugs selected have NOT been designed for CNS cancers).

It is an incredible development and endorsement for KZA to be approached to use our drug y ALLIANCE...yet in the last month since the announcement, our SP has declined by 25% into a cap of just US$14m. Truly pitiful.

Should the research and very current views of ALLIANCE and Dr B - be proven to be correct and subsequently GDC 0084 reaches the market

.....according to the KZA CEO, our market value could reach one billion dollars....that would be under a licensing deal whereby Kazia would sell the rights to GDC 0084 on the basis of 10 to 15% futures royalties on gross world sales. (which is a standard small biotech / BigPharma type deal).  Some cash maybe $20m upfront could mean no further raising by KZA), thus without further dilution leading to a SP of ….(you work it out)